Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

Robert Knobler; Marija Geroldinger-Simić; Alexander Kreuter; Nicolas Hunzelmann; Pia Moinzadeh; Franco Rongioletti; Christopher Denton; Luc Mouthon; Maurizio Cutolo; Vanessa Smith; Armando Gabrielli; Martine Bagot; Anne B. Olesen; Ivan Foeldvari; Ahmad Jalili; Veli Matti Kähäri; Sarolta Kárpáti; Kristian Kofoed; Malgorzata Olszewska; Jaana Panelius; Pietro Quaglino; Julien Seneschal; Michael Sticherling; Cord Sunderkötter; Adrian Tanew; Peter Wolf; Margitta Worm; Anna Skrok; Lidia Rudnicka; Thomas Krieg

doi:10.1111/jdv.19937

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

Robert Knobler^*, Marija Geroldinger-Simić, Alexander Kreuter, Nicolas Hunzelmann, Pia Moinzadeh, Franco Rongioletti, Christopher Denton, Luc Mouthon, Maurizio Cutolo, Vanessa Smith, Armando Gabrielli, Martine Bagot, Anne B. Olesen, Ivan Foeldvari, Ahmad Jalili, Veli Matti Kähäri, Sarolta Kárpáti, Kristian Kofoed, Malgorzata Olszewska, Jaana PaneliusPietro Quaglino, Julien Seneschal, Michael Sticherling, Cord Sunderkötter, Adrian Tanew, Peter Wolf, Margitta Worm, Anna Skrok, Lidia Rudnicka, Thomas Krieg

^*Corresponding author for this work

Department of Clinical Medicine - The Department of Dermatology and Venereology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

Abstract

The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	38
Issue	7
Pages (from-to)	1281-1299
Number of pages	19
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.19937
Publication status	Published - Jul 2024

Access to Document

10.1111/jdv.19937Licence: CC BY-NC

Cite this

Knobler, R., Geroldinger-Simić, M., Kreuter, A., Hunzelmann, N., Moinzadeh, P., Rongioletti, F., Denton, C., Mouthon, L., Cutolo, M., Smith, V., Gabrielli, A., Bagot, M., Olesen, A. B., Foeldvari, I., Jalili, A., Kähäri, V. M., Kárpáti, S., Kofoed, K., Olszewska, M., ... Krieg, T. (2024). Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema. Journal of the European Academy of Dermatology and Venereology, 38(7), 1281-1299. https://doi.org/10.1111/jdv.19937

@article{c4fdfa84ab694623981e6f9d2d919c30,

title = "Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema",

abstract = "The term {\textquoteleft}sclerosing diseases of the skin{\textquoteright} comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).",

author = "Robert Knobler and Marija Geroldinger-Simi{\'c} and Alexander Kreuter and Nicolas Hunzelmann and Pia Moinzadeh and Franco Rongioletti and Christopher Denton and Luc Mouthon and Maurizio Cutolo and Vanessa Smith and Armando Gabrielli and Martine Bagot and Olesen, {Anne B.} and Ivan Foeldvari and Ahmad Jalili and K{\"a}h{\"a}ri, {Veli Matti} and Sarolta K{\'a}rp{\'a}ti and Kristian Kofoed and Malgorzata Olszewska and Jaana Panelius and Pietro Quaglino and Julien Seneschal and Michael Sticherling and Cord Sunderk{\"o}tter and Adrian Tanew and Peter Wolf and Margitta Worm and Anna Skrok and Lidia Rudnicka and Thomas Krieg",

year = "2024",

month = jul,

doi = "10.1111/jdv.19937",

language = "English",

volume = "38",

pages = "1281--1299",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Elsevier",

number = "7",

}

Knobler, R, Geroldinger-Simić, M, Kreuter, A, Hunzelmann, N, Moinzadeh, P, Rongioletti, F, Denton, C, Mouthon, L, Cutolo, M, Smith, V, Gabrielli, A, Bagot, M, Olesen, AB, Foeldvari, I, Jalili, A, Kähäri, VM, Kárpáti, S, Kofoed, K, Olszewska, M, Panelius, J, Quaglino, P, Seneschal, J, Sticherling, M, Sunderkötter, C, Tanew, A, Wolf, P, Worm, M, Skrok, A, Rudnicka, L & Krieg, T 2024, 'Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema', Journal of the European Academy of Dermatology and Venereology, vol. 38, no. 7, pp. 1281-1299. https://doi.org/10.1111/jdv.19937

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema. / Knobler, Robert; Geroldinger-Simić, Marija; Kreuter, Alexander et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 38, No. 7, 07.2024, p. 1281-1299.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

TY - JOUR

T1 - Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2

T2 - Scleromyxoedema and scleroedema

AU - Knobler, Robert

AU - Geroldinger-Simić, Marija

AU - Kreuter, Alexander

AU - Hunzelmann, Nicolas

AU - Moinzadeh, Pia

AU - Rongioletti, Franco

AU - Denton, Christopher

AU - Mouthon, Luc

AU - Cutolo, Maurizio

AU - Smith, Vanessa

AU - Gabrielli, Armando

AU - Bagot, Martine

AU - Olesen, Anne B.

AU - Foeldvari, Ivan

AU - Jalili, Ahmad

AU - Kähäri, Veli Matti

AU - Kárpáti, Sarolta

AU - Kofoed, Kristian

AU - Olszewska, Malgorzata

AU - Panelius, Jaana

AU - Quaglino, Pietro

AU - Seneschal, Julien

AU - Sticherling, Michael

AU - Sunderkötter, Cord

AU - Tanew, Adrian

AU - Wolf, Peter

AU - Worm, Margitta

AU - Skrok, Anna

AU - Rudnicka, Lidia

AU - Krieg, Thomas

PY - 2024/7

Y1 - 2024/7

N2 - The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).

AB - The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).

U2 - 10.1111/jdv.19937

DO - 10.1111/jdv.19937

M3 - Review

C2 - 38456518

AN - SCOPUS:85187891366

SN - 0926-9959

VL - 38

SP - 1281

EP - 1299

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

Abstract

Access to Document

Fingerprint

Cite this